State Street Corp Vaxcyte, Inc. Transaction History

State Street Corp

$2.59 Trillion
Q2 2025

A detailed history of State Street Corp transactions in Vaxcyte, Inc. stock. As of the latest transaction made, State Street Corp holds 4,942,235 shares of PCVX stock, worth $148 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

4,942,235

Previous 4,407,683 12.13%

Holding current value

$148 Million

Previous $166 Million 3.46%

% of portfolio

0.01%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$28.04 - $37.2 $15 Million - $19.9 Million	534,552 Added 12.13%	4,942,235 $161 Million
Q1 2025 May 15, 2025	SELL	$37.76 - $92.13 $4.97 Million - $12.1 Million	-131,723 Reduced 2.9%	4,407,683 $166 Million
Q4 2024 Feb 14, 2025	BUY	$80.97 - $117.93 $91.8 Million - $134 Million	1,133,663 Added 33.29%	4,539,406 $372 Million
Q3 2024 Nov 14, 2024	BUY	$70.52 - $117.12 $2.72 Million - $4.52 Million	38,596 Added 1.15%	3,405,743 $389 Million
Q2 2024 Aug 14, 2024	BUY	$60.06 - $78.77 $1.81 Million - $2.37 Million	30,055 Added 0.9%	3,367,147 $254 Million
Q1 2024 May 15, 2024	SELL	$59.79 - $81.05 $3.14 Million - $4.25 Million	-52,436 Reduced 1.55%	3,337,092 $228 Million
Q4 2023 Feb 14, 2024	BUY	$45.35 - $63.41 $11.1 Million - $15.5 Million	244,269 Added 7.77%	3,389,528 $213 Million
Q3 2023 Nov 14, 2023	SELL	$46.0 - $53.1 $830,438 - $958,614	-18,053 Reduced 0.57%	3,145,259 $160 Million
Q2 2023 Aug 14, 2023	BUY	$34.66 - $54.07 $3.03 Million - $4.72 Million	87,296 Added 2.84%	3,163,312 $158 Million
Q1 2023 May 15, 2023	SELL	$36.27 - $47.2 $3.34 Million - $4.34 Million	-91,965 Reduced 2.9%	3,076,016 $115 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $24.2 Million - $56.3 Million	1,174,945 Added 58.95%	3,167,981 $152 Million
Q3 2022 Nov 15, 2022	BUY	$21.69 - $28.53 $2.98 Million - $3.92 Million	137,392 Added 7.4%	1,993,036 $47.8 Million
Q2 2022 Aug 15, 2022	BUY	$17.68 - $26.58 $8.34 Million - $12.5 Million	471,476 Added 34.06%	1,855,644 $40.4 Million
Q1 2022 May 16, 2022	BUY	$17.46 - $26.36 $3.65 Million - $5.52 Million	209,237 Added 17.81%	1,384,168 $33.4 Million
Q4 2021 Feb 14, 2022	BUY	$19.32 - $26.45 $747,239 - $1.02 Million	38,677 Added 3.4%	1,174,931 $28 Million
Q3 2021 Nov 15, 2021	SELL	$20.26 - $26.97 $7.44 Million - $9.9 Million	-367,009 Reduced 24.41%	1,136,254 $28.8 Million
Q2 2021 Aug 16, 2021	SELL	$16.45 - $24.06 $4.42 Million - $6.47 Million	-268,813 Reduced 15.17%	1,503,263 $33.8 Million
Q1 2021 May 17, 2021	BUY	$18.66 - $29.16 $15.9 Million - $24.8 Million	850,246 Added 92.23%	1,772,076 $35 Million
Q4 2020 Feb 16, 2021	BUY	$26.57 - $51.74 $17.2 Million - $33.5 Million	647,789 Added 236.38%	921,830 $24.5 Million
Q3 2020 Nov 10, 2020	BUY	$26.5 - $55.4 $7.26 Million - $15.2 Million	274,041 New	274,041 $13.5 Million

Others Institutions Holding PCVX

# of Institutions

323

Shares Held

139M

Call Options Held

229K

Put Options Held

160K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $1.78B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Vaxcyte, Inc. Transaction History